FutureFemHealth

FutureFemHealth

Home
Work with us / Advertise
CensHERship
Archive
About
Gedeon Richter signs deal with Swiss biotech FimmCyte to develop potential endometriosis antibody
An early step towards disease-modifying treatment
 • Anna O'Sullivan
💌 Issue 134: Bank blocking bias | Matresa pre-seed | Mira x ŌURA partnership | theblood validates menstrual blood diagnostics |
The global weekly briefing on women's health innovation and Femtech
 • Anna O'Sullivan
Matresa raises £315,000 pre-seed to address UK maternal health crisis
Continuous, personalised support from pregnancy through to early parenthood.
 • Anna O'Sullivan
Mira and ŌURA link hormone testing with wearable data in new app integration
Partnership brings together lab-grade hormone readings and sleep and temperature trends, as women’s health tech firms race to combine previously siloed…
 • Anna O'Sullivan
theblood partners with SGS to validate menstrual blood diagnostics
Menstrual blood is increasingly being explored as a potential source of biomarkers linked to female-specific conditions
 • Anna O'Sullivan
Women's health businesses face hidden barriers in banking, payments and business insurance - new report
New research from CensHERship and The Case for Her explores barriers for legitimate companies
 • Anna O'Sullivan
💌 Issue 133: Menstrual blood diagnostics | $55m for overlooked heart disease | Clair moves out of stealth | Calla Lily lands Merck
The global weekly briefing on women's health innovation and Femtech
 • Anna O'Sullivan
Menstrual blood diagnostics in 2026: what's changing - and what we're tracking
FFHi - Brief: Why menstrual blood diagnostics are entering the mainstream — and what will determine whether they scale
 • Anna O'Sullivan
Clair emerges from stealth with plans to launch continuous hormone tracking wearable
Tracks hormonal dynamics in real time, without relying on blood draws, urine tests or needles
 • Anna O'Sullivan
Breaking down silos: why women’s health data needs a different future
As women’s health data explodes across apps, wearables and clinical systems, fragmentation — not scarcity — may be the biggest barrier to meaningful…
 • Anna O'Sullivan and Sophie Louise Feith
Calla Lily secures Merck as first industry partner for intravaginal drug delivery platform
Strategic partnership will support the continued development of Callavid®, its novel intravaginal drug delivery platform
 • Anna O'Sullivan
Wellcome Leap launches $55m program to tackle overlooked heart disease in women
Jointly funded with Pivotal and supported by the British Heart Foundation
 • Anna O'Sullivan
© 2026 FutureFemHealth · Privacy ∙ Terms ∙ Collection notice
Start your SubstackGet the app
Substack is the home for great culture